Stockreport

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis wit...

Prothena Corporation plc - Ordinary Shares  (PRTA) 
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.prothena.com
PDF Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy Prothena has now earned $150 million to da [Read more]